Therapeutic Effect of Glucosamine on an Atopic Dermatitis Animal Model
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Recent studies have reported that glucosamine (GlcN) showed therapeutic effects in allergic diseases such as asthma and rhinitis, and its mechanisms include the suppression of T helper type 2 immune responses and the nuclear factor-κB pathway. Objective: We aimed to investigate the effect of GlcN on atopic dermatitis (AD) in an animal model. Methods: Twenty-five BALB/c mice were divided into five groups (groups A∼E). Group A was the phosphate- buffered saline (PBS)-treated group without AD induction. Group B was the PBS control group with AD induction. Groups C to E were the AD induction groups, which were treated with three different doses of GlcN (10 mg, 20 mg, and 40 mg, respectively). Histopathological examination was performed after GlcN administration. Interleukin (IL)-4, IL-13, and IL-17 cytokine levels were measured by enzyme- linked immunosorbent assay using skin biopsy specimens. Serum total immunoglobulin E (IgE) concentrations were measured before and after administration with GlcN or PBS. Results: Clinical dermatitis scores decreased with increasing GlcN dose (p＜0.001). Concentrations of tissue IL-13 and IL-17 decreased after GlcN administration (each group: p=0.002 and p＜0.001, respectively), but the concentrations of tissue IL-4 did not show differences across groups. Serum IgE levels tended to be lower after GlcN administration (p=0.004). Histopathological scores were not significantly different among groups B∼E (p=0.394). Conclusion: GlcN improved AD symptoms and decreased tissue IL-13, IL-17, and serum total IgE levels in an animal model.
Abstract
Background: Recent studies have reported that glucosamine (GlcN) showed therapeutic effects in allergic diseases such as asthma and rhinitis, and its mechanisms include the suppression of T helper type 2 immune responses and the nuclear factor-κB pathway. Objective: We aimed to investigate the effect of GlcN on atopic dermatitis (AD) in an animal model. Methods: Twenty-five BALB/c mice were divided into five groups (groups A∼E). Group A was the phosphate- buffered saline (PBS)-treated group without AD induction. Group B was the PBS control group with AD induction. Groups C to E were the AD induction groups, which were treated with three different doses of GlcN (10 mg, 20 mg, and 40 mg, respectively). Histopathological examination was performed after GlcN administration. Interleukin (IL)-4, IL-13, and IL-17 cytokine levels were measured by enzyme- linked immunosorbent assay using skin biopsy specimens. Serum total immunoglobulin E (IgE) concentrations were measured before and after administration with GlcN or PBS. Results: Clinical dermatitis scores decreased with increasing GlcN dose (p＜0.001). Concentrations of tissue IL-13 and IL-17 decreased after GlcN administration (each group: p=0.002 and p＜0.001, respectively), but the concentrations of tissue IL-4 did not show differences across groups. Serum IgE levels tended to be lower after GlcN administration (p=0.004). Histopathological scores were not significantly different among groups B∼E (p=0.394). Conclusion: GlcN improved AD symptoms and decreased tissue IL-13, IL-17, and serum total IgE levels in an animal model.
참고문헌 (16)
- Peng W, "Pathogenesis of atopic dermatitis", Clin Exp Allergy, 45, pp.566~574 (2015)
- Egawa G, "Pathogenesis of atopic dermatitis : a short review", Cogent Biol, 1, pp.1103459~ (2015)
- Koga C, "Possible pathogenic role of Th17 cells for atopic dermatitis", J Invest Dermatol, 128, pp.2625~2630 (2008)
- Vaneckova J, "The severity of atopic dermatitis and the relation to the level of total IgE, onset of atopic dermatitis and family history about atopy", Food Agric Immunol, 27, pp.734~741 (2016)
- Sidbury R, "Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents", J Am Acad Dermatol, 71, pp.327~349 (2014)
- Gooderham MJ, "Dupilumab:a review of its use in the treatment of atopic dermatitis", J Am Acad Dermatol, 78(3 Suppl 1), pp.S28~S36 (2018)
- Jung AY, "Glucosamine has an antiallergic effect in mice with allergic asthma and rhinitis", Int Forum Allergy Rhinol, 7, pp.763~769 (2017)
- Nakamura H, "Effects of glucosamine administration on patients with rheumatoid arthritis", Rheumatol Int, 27, pp.213~218 (2007)
- Reginster JY, "Long-term effects of glucosamine sulphate on osteoarthritis progression : a randomised, placebo-controlled clinical trial", Lancet, 357, pp.251~256 (2001)
- Kim CH, "Glucosamine improved atopic dermatitis-like skin lesions in NC", Nga mice by inhibition of Th2 cell development, 2011, pp.73, 536~545
- Jin SE, "Antiallergic activity of crystallinity controlled N-acetyl glucosamine", Immunopharmacol Immunotoxicol, 34, pp.991~1000 (2012)
- Forchhammer L, "Immunobiological effects of glucosamine in vitro", Scand J Immunol, 58, pp.404~411 (2003)
- Pauwels R, "The effect of age on IgE production in rats", Immunology, 36, pp.145~149 (1979)
- Rafi MM, "Glucosamine inhibits LPSinduced COX-2 and iNOS expression in mouse macrophage cells (RAW 264.7) by inhibition of p38-MAP kinase and transcription factor NF-kappaB", Mol Nutr Food Res, 51, pp.587~593 (2007)
- Hwang JS, "Lipopolysaccharide(LPS)-stimulated iNOS induction is increased by glucosamine under normal glucose conditions but Is inhibited by glucosamine under high glucose conditions in macrophage cells", J Biol Chem, 292, pp.1724~1736 (2017)
- Zahedipour F, "Molecular mechanisms of anticancer effects of Glucosamine", Biomed Pharmacother, 95, pp.1051~1058 (2017)